This grade answers one narrow question: how strong is the public evidence and safety record behind this drug, and how clean is its money trail and court record? It is not a verdict on whether the drug is right for you.
WARNING: ABUSE, MISUSE, AND ADDICTION Methylphenidate HCl Extended-Release Tablets have a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including Methylphenidate HCl Extended-Release Tablets, can result in overdose and death [see Overdosage (10) ] , and this risk is increased with a higher dosage or unapproved methods of administration, such as snorting or injection. Before prescribing Methylphenidate HCl Extended-Release Tablets, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of Methylphenidate HCl Extended-Release Tablets, and proper disposal of any unused drug. Throughout Methylphenidate HCl Extended-Release Tablets treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see Warnings and Precautions (5.1 ) and Drug Abuse and Dependence (9.1, 9.2 ) ] . WARNING: ABUSE, MISUSE, AND ADDICTION See full prescribing information for complete boxed warning. Methylphenidate HCl Extended-Release Tablets h...
Warnings the FDA chose to announce publicly after approval, as opposed to quiet label edits. Class-wide items name the drug's class, not this drug specifically.
Methylphenidate HCl Extended-Release Tablets are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 6 to 65 years old. Limitations of Use The use of Methylphenidate HCl Extended-Release Tablets is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions (5.7) and Use in Specific Populations (8.4) ]. Methylphenidate HCl Extended-Release Tablets are a CNS stimulant indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 6 to 65 years old. ( 1 ) Limitations of Use The use of Methylphenidate HCl Extended-Release Tablets is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage ( 5.7 , 8.4 ).
Methylphenidate HCl Extended-Release Tablets are contraindicated in patients: Known to be hypersensitive to methylphenidate or other components of Methylphenidate HCl Extended-Release Tablets. Hypersensitivity reactions, such as angioedema and anaphylactic reactions, have been reported in patients treated with Methylphenidate HCl Extended-Release Tablets [see Adverse Reactions (6) ] . Receiving concomitant monoamine oxidase inhibitors (MAOIs), and within 14 days following discontinuation of treatment with a MAO inhibitor because of the risk of a hypertensive crisis [see Drug Interactions (7) ] . Known hypersensitivity to methylphenidate or other components of Methylphenidate HCl Extended-Release Tablets ( 4 ) Receiving concomitant monoamine oxidase inhibitors and within 14 days following discontinuation of treatment with a MAO inhibitor ( 4 )
Risks to Patients with Serious Cardiac Disease : Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmias, coronary artery disease, or other serious cardiac disease. ( 5.2 ) Increased Blood Pressure and Heart Rate : Monitor blood pressure and pulse. ( 5.3 ) Psychiatric Adverse Reactions : Prior to initiating Methylphenidate HCl Extended-Release Tablets, screen patients for risk factors for developing a manic episode. If new psychotic or manic symptoms occur, consider discontinuing Methylphenidate HCl Extended-Release Tablets. ( 5.4 ) Priapism : If abnormally sustained or frequent and painful erections occur, patients should seek immediate medical attention. ( 5.5 ) Peripheral Vasculopathy, including Raynaud’s Phenomenon : Carefully assess for digital changes during Methylphenidate HCl Extended-Release Tablets treatment. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for patients who develop signs or symptoms of peripheral vasculopathy. ( 5.6 ) Long-Term Suppression of Growth in Pediatric Patients : Closely monitor growth (height and weight) in pediatric patients. Pediatric patients not growing or ga...
The following are discussed in more detail in other sections of the labeling: Abuse, Misuse, and Addiction [see Boxed Warning , Warnings and Precautions ( 5.1 ) , Drug Abuse and Dependence (9.2) ] Hypersensitivity Reactions [see Contraindications (4) ] Monoamine Oxidase Inhibitors [see Contraindications (4) , Drug Interactions (7) ] Risks to Patients with Serious Cardiac Disease [see Warnings and Precautions (5.2) ] Increased Blood Pressure and Heart Rate [see Warnings and Precautions (5.3) ] Psychiatric Adverse Reactions [see Warnings and Precautions (5.4) ] Priapism [see Warnings and Precautions (5.5) ] Peripheral Vasculopathy, including Raynaud’s Phenomenon [see Warnings and Precautions (5.6) ] Long-Term Suppression of Growth in Pediatric Patients [see Warnings and Precautions (5.7) ] Risks of Gastrointestinal Obstruction in Patients with Gastrointestinal Narrowing [see Warnings and Precautions (5.8) ] Acute Angle Closure Glaucoma [see Warnings and Precautions (5.9) ] Increased Intraocular Pressure and Glaucoma [see Warnings and Precautions (5.10) ] Motor and Verbal Tics, and Worsening of Tourette’s Syndrome [see Warnings and Precautions (5.11) ] The most common adverse reaction...
Boxed Warning 10/2023 Indications and Usage ( 1 ) 10/2023 Dosage and Administration ( 2.1 , 2.6 ) 10/2023 Dosage and Administration, Maintenance/Extended Treatment ( 2.5 ) Removed 10/2023 Contraindications ( 4 ) 10/2023 Warnings and Precautions ( 5.1 , 5.2, 5.3 , 5.4 , 5.6 , 5.7 , 5.8 , 5.11 , 5.12 , 5.13 ) 10/2023 Warnings and Precautions ( 5.7 ) Removed 10/2023 Indications and Usage ( 1 ) 09/2025 Dosage and Administration ( 2.3 , 2.4 ) 02/2026 Warnings and Precautions: Long-Term Suppression of Growth in Pediatric Patients 09/2025 Warnings and Precautions: Removal Seizures and Hematologic Monitoring 02/2026
Source: FDA SPL label for Methylphenidate Hydrochloride (Lannett Company, Inc.), effective 20260501. Full label on DailyMed.
These are counts of reports people filed, not rates of harm. Anyone can file one, and nobody checks whether the drug was the cause. Millions of doses are taken for every report sent, so the useful part is how this drug compares with the average across all drugs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| 4,625 | 3,700 | 3,240 | 3,542 | 4,089 | 3,853 | 3,933 | 1,842 |
10,344 reports blaming this drug for every million Medicare prescriptions filled, which is 3.7× the typical drug on this site. (9,518 reports in 2024–2026, against 920,163 Medicare fills in one year. This is the one number here that accounts for how many people take the drug.)
Source: the FDA's Adverse Event Reporting System (FAERS). Reports are voluntary and unverified. Drugs that are prescribed a lot, in the news, or in lawsuits attract more reports, so the percentages are compared with the whole database to correct for that partly, not fully.
| Date | Class | Firm | Reason |
|---|---|---|---|
| 06/2024 | Class II | Trigen Laboratories | Failed dissolution specifications: this product is being recalled due to this batch not meeting dissolution specifications. |
| 07/2023 | Class II | SUN PHARMACEUTICAL INDUSTRIES INC | Presence of Foreign Substance: Metal embedded in a tablet. |
| 03/2023 | Class II | Noven Pharmaceuticals Inc | Defective Delivery System: Out of specification for shear. |
| 03/2023 | Class II | Noven Pharmaceuticals Inc | Defective Delivery System: Out of specification for shear. |
| 03/2023 | Class II | Noven Pharmaceuticals Inc | Defective Delivery System: Out of specification for shear. |
| 03/2023 | Class II | Noven Pharmaceuticals Inc | Defective Delivery System: Out of specification for shear. |
| 11/2022 | Class II | Noven Pharmaceuticals Inc | Defective Delivery System: Recalled lot was found to be out of specification for shear. Shear is an attribute related to the adhesive properties of the transdermal patches. |
| 06/2022 | Class II | Noven Pharmaceuticals Inc | Defective Delivery System: Customer complaints received for ripping patches and tight release/adhesive transfer. |
| 05/2022 | Class II | Noven Pharmaceuticals Inc | Defective Delivery System: customer complaints exceeded respective action limits. |
| 02/2022 | Class II | RISING PHARMACEUTICALS | Failed Tablet Specifications: Recall of this drug product was voluntarily initiated by the manufacturer due to a market complaint, which stated that a tablet in the sealed bottle was twice larger in size when compared to the remaining table |
| 05/2021 | Class II | Noven Pharmaceuticals Inc | Defective Delivery System: The number of customer complaints for ripping patches and tight release/adhesive transfer have exceeded the action limits. |
| 05/2021 | Class II | Noven Pharmaceuticals Inc | Defective Delivery System: The number of customer complaints for ripping patches and tight release/adhesive transfer have exceeded the action limits. |
Class I = reasonable probability of serious harm. Class II = temporary or reversible harm. Class III = unlikely to harm. Most generic recalls are manufacturing or labeling defects for one lot, not a verdict on the molecule.
Counts measure how much evidence exists and how transparent it is, not how big the benefit is. For that, ask your prescriber: if 100 people like me took this, how many would get better because of it, and how many would be harmed? (Doctors call these the "number needed to treat" and "number needed to harm.") It differs by condition and is the number drug ads leave out. Sources: PubMed, ClinicalTrials.gov.
In 2024, drug companies reported $59,319 in payments to US physicians and hospitals tied to this drug across 2,869 transactions (Relexxii $58,356, Quillivant $964).
No pending federal MDL names this drug or its brands.
Not named in any federal pharmaceutical settlement of $100M or more on record.
Sources: CMS Open Payments (Sunshine Act); Judicial Panel on Multidistrict Litigation pending docket list; DOJ settlements as tabulated on Wikipedia with links to the primary record. State-court and individual suits are not included.
| Product | Fills | $/fill |
|---|---|---|
| Methylphenidate HCl | 612,748 | $25 |
| Methylphenidate ER | 225,973 | $88 |
| Methylphenidate ER (La) | 25,549 | $129 |
| Concerta | 19,317 | $546 |
| Methylphenidate HCl ER (Cd) | 15,437 | $86 |
| Methylphenidate HCl CD | 8,038 | $88 |
| Ritalin | 5,652 | $127 |
| Jornay PM | 2,964 | $474 |
Same ATC pharmacological class, graded ones first, best grade at the top. Being in the same class does not make them interchangeable for your condition; it makes them worth asking about.